Daily Respiratory Research Analysis
Analyzed 165 papers and selected 3 impactful papers.
Summary
Analyzed 165 papers and selected 3 impactful articles.
Selected Articles
1. IL-33 Drives Inflammatory Changes and Extracellular Trap Formation in Eosinophils Involving Oxidised LDL and Complement Pathways.
Using primary human eosinophils with multi-omics and imaging, the authors show that IL-33 triggers an inflammatory program and extracellular trap formation (ETosis), with upregulation of OLR1, CD22, CD4 and ICAM-1. Oxidized LDL and complement fragments modulate eosinophil survival and adhesion, and IL-33-induced ETosis depends on NADPH oxidase, MAPK and PI3K pathways. Eosinophils from nasal polyps mirror IL-33–induced signatures, highlighting druggable pathways in eosinophilic airway disease.
Impact: This work uncovers a mechanistic axis (IL-33–oxLDL–complement) that drives eosinophil ETosis and inflammatory reprogramming, providing concrete targets beyond canonical type 2 cytokines for severe asthma and related disorders.
Clinical Implications: Therapeutic strategies blocking IL-33/ST2, OLR1 (oxidized LDL receptor), or complement activation may reduce eosinophil ETosis and tissue damage in severe asthma and chronic rhinosinusitis with nasal polyps.
Key Findings
- IL-33 and TNF-α induce an inflammatory gene signature in eosinophils, upregulating OLR1, CD22, CD4, and ICAM-1; CD22 upregulation was specific to IL-33.
- Eosinophils from nasal polyps exhibited gene-expression profiles similar to IL-33–stimulated cells, supporting in vivo relevance.
- Oxidized LDL and complement fragments (C3a, C5a) differentially prolonged eosinophil survival and altered adhesion molecule expression.
- IL-33 triggered eosinophil extracellular trap formation (ETosis) via NADPH oxidase, MAPK, and PI3K pathways.
Methodological Strengths
- Integrated multi-omics (transcriptomics and proteomics) with functional assays and imaging of ETosis
- Use of primary human eosinophils and validation in tissue-derived eosinophils from nasal polyps
Limitations
- Predominantly in vitro/ex vivo human cell work without interventional in vivo models
- Sample sizes and donor heterogeneity are not detailed in the abstract, limiting generalizability
Future Directions: Test IL-33/ST2, OLR1, and complement-targeted interventions in animal models and early clinical trials; stratify eosinophilic airway disease by ETosis-prone molecular signatures.
BACKGROUND: IL-33 levels are elevated in the airways of patients with eosinophilic diseases, and IL-33 receptor expression on eosinophils is upregulated in type 2-high environments. However, the role of IL-33 in the regulation of human eosinophils remains unclear. OBJECTIVE: To elucidate the inflammatory effects of IL-33 on the cellular function of human eosinophils. METHODS: Blood eosinophils were stimulated with IL-33, TNF-α, oxidised low-density lipoprotein (oxLDL) and complement fragments (C3a and C5a). Multi-omics analyses, including transcriptomics and proteomics, were performed. Extracellular trap form
2. AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.
In 93,326 primary-care chest X-rays randomized by day to AI worklist prioritization on versus off, there were no significant differences in time to CT (both medians 53 days) or lung cancer diagnosis (44 vs 46 days), nor in urgent referral, time to treatment, or stage. Discordance between AI and radiology reports occurred in 30.3% of CXRs; expert review found actionable findings in 6,750 cases. Findings argue against using AI for worklist prioritization in this pathway.
Impact: This pragmatic, negative RCT at national scale directly informs AI deployment strategy in cancer diagnostics, demonstrating no pathway acceleration from worklist prioritization.
Clinical Implications: Do not implement CXR AI as a worklist prioritizer in UK primary care lung cancer pathways; instead, focus on accuracy, triage rules, or targeted downstream interventions where AI may add value.
Key Findings
- No reduction in time to CT with AI prioritization: median 53 days in both arms; ratio of geometric means 0.97 (95% CI 0.93–1.02; P=0.31).
- No reduction in time to lung cancer diagnosis: 44 vs 46 days; ratio of geometric means 0.98 (95% CI 0.83–1.16; P=0.84).
- No differences in urgent referral time (14 vs 15 days; P=0.13), time to treatment (76 vs 72.5 days; P=0.99), or stage at diagnosis (P=0.34).
- AI–radiology report discordance in 28,261 CXRs (30.3%); expert review identified actionable findings in 6,750 cases (23.9%).
Methodological Strengths
- Prospective, multicentre, randomized design with very large sample size (93,326 CXRs).
- Pragmatic evaluation embedded in real-world primary care pathways with prespecified outcomes.
Limitations
- Randomization by day may allow temporal confounding and operational variability.
- AI availability in both arms may dilute effects of prioritization; generalizability outside UK primary care uncertain.
Future Directions: Test alternative AI integration points (e.g., accuracy triage, direct referral triggers, clinician-AI interaction design) and measure patient-centric outcomes, resource use, and equity impacts.
Prioritizing artificial intelligence (AI)-detected imaging findings may reduce the time to diagnosis of lung cancer. This prospective, multicentre, randomized controlled trial tested whether immediate AI prioritization of primary care-requested chest X-rays (CXR) influenced time to computed tomography (CT) and lung cancer diagnosis, the primary outcomes. Secondary outcomes included the number of urgent suspected lung cancer referrals, incidence and stage of lung cancer, times to urgent referral and treatment, concordanc
3. Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial.
Among 232 ventilated infants with bronchiolitis randomized to endotracheal poractant alfa (200 mg/kg then 100 mg/kg q12h up to 3 doses) versus sham, the duration of invasive mechanical ventilation did not differ (64.9 h vs 62.0 h; geometric mean ratio 1.02; P=0.86). No clinically significant safety issues and no deaths occurred.
Impact: This high-quality negative RCT addresses a widely discussed off-label intervention in PICUs, providing definitive evidence against routine surfactant use for early critical bronchiolitis.
Clinical Implications: Endotracheal poractant alfa should not be used to reduce ventilation duration in early critical bronchiolitis at the tested dose and schedule; resources should shift to evidence-based supportive strategies.
Key Findings
- No reduction in duration of invasive mechanical ventilation: 64.9 h (IQR 43.2–92.1) vs 62.0 h (39.3–95.1); geometric mean ratio 1.02 (95% CI 0.84–1.24); P=0.86.
- Dosing regimen: initial 200 mg/kg, then 100 mg/kg at 12-hour intervals, up to three doses.
- Safety: no clinically significant safety issues; no deaths reported.
Methodological Strengths
- Multicentre, randomized, blinded, sham-controlled design with prespecified primary endpoint.
- Mechanistic substudies planned, and rigorous dosing protocol.
Limitations
- Phase 2 sample size may limit detection of subgroup effects.
- Findings pertain to early critical bronchiolitis under invasive ventilation and tested dosing; other timings or formulations not assessed.
Future Directions: Prioritize trials of supportive care optimization (ventilation strategies, secretion management) and identify phenotypes where adjunctive therapies might benefit, with patient-centred outcomes.
BACKGROUND: Bronchiolitis is a common viral respiratory disease of infants, with severity ranging from mild symptoms, such as coryza and feeding difficulties, to fulminant respiratory failure. Endotracheal administration of exogenous surfactant has been shown in small studies to improve gas exchange in critically ill infants with bronchiolitis. We aimed to investigate the safety and efficacy of endotracheal poractant alfa for treating critical bronchiolitis compared with a sham procedure. METHODS: BESS was a multic